Biodegradable implants with hydrophobic coating for the treatment of dopamine associated states

ABSTRACT - 596297 The disclosure relates to a use of a biocompatible and/or biodegradable polymer and an effective amount of a dopamine modulating compound in the manufacture of a biodegradable implant for treating a subject for a dopamine associated state, wherein said dopamine modulating compound is a dopamine agonist selected from the group consisting of apomorphine, lisuride, pergolide, bromocriptine, pramipexole, rotigotine, docarpamine, terguride, cabergoline, levodopa, spheramine, romergoline, carmoxirole, zelandopam, sumanirole, sibenadet, a 4-alkylamino-2(3H)-indolone compound, a compound of formula (I), ropinrole, and any combination thereof, wherein R is amino, alkylamino, di-alkylamino, alkenylamino, dialkenylamino, N-alkyl-N-alkenylamino, benzylamino, dibenzylamino, aryl alkyl amino , or diarylalkylamino; R1, R2 and R3 are each independently hydrogen or alkyl; and n is 1, 2, or 3, or a pharmaceutically acceptable salt thereof; wherein said implant comprises a hydrophobic coating comprising one or more hydrophobic polymers selected from the group consisting of polyglycolide (PLGA), polycapralactone (PCL), poly-L-lactic acid (PLA), ethylcellulose, and copolymers thereof, and wherein said dopamine associated state is Parkinson's disease, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism, pervasive development disorder (PDD), Asberger's syndrome, toxin- induced parkinsonism, disease-induced parkinsonism, erectile dysfunction, restless leg syndrome, or hyperprolactinemia.